Sociedad Americana de Hirudoterapia

Food and Drugs Authority — Ghana

FDA Ghana · Ghana · africa

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Ghana's Food and Drugs Authority — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework or traditional medicine pathways as appropriate.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
Ghana
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Ghanaian Public Health Act (Act 851) — provisions on food, drugs, and devices
  • Ghanaian framework for traditional and alternative medicine practice as appropriate

Prescriber Requirements

  • Medical and Dental Council of Ghana–registered physician — order required for any biomedical device application
  • Traditional medicine practitioners registered under the Traditional Medicine Practice Council may have separate scope; specific hirudotherapy authorisation not independently verified by ASH

Supply Chain & GMP

FDA Ghana registration as applicable; English-language labelling. Standard cold-chain conditions.

Import/Export Rules

FDA Ghana import authorisation; Veterinary Services Directorate clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Ghana has statutory recognition of traditional medicine through the Traditional Medicine Practice Council; whether leech therapy falls under that framework or under FDA Ghana's medical-device pathway has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.